Minimal residual disease in head and neck cancer

Cancer and Metastasis Reviews

Volumn 18, Issue 1, 1999, Pages 109-126

  Gath, Hans J ^a   Brakenhoff, Ruud H ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Head and neck cancer; Minimal residual disease; Molecular staging; Squamous cell carcinoma

Indexed keywords

ACETYLCYSTEINE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; ISOTRETINOIN; METHOTREXATE; MONOCLONAL ANTIBODY; TAXOID;

ARTICLE; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC PROCEDURE; HEAD AND NECK CANCER; HUMAN; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT PLANNING;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; NEOPLASM, RESIDUAL;

EID: 0032849292     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006268621730     Document Type: Article

References (136)

1. Boring CC, Squires TS, Tong T: Cancer statistics, 1992. CA Cancer J Clin. 42: 19-38, 1992
2. Howaldt HP, Kainz M: Projektbericht des Zentral-registers der Deutsch-Österreichisch-Schweizerischen Arbeiteitskreises für Tumoren im Kiefer- und Gesichts-bereich November 1997
3. Franceschi D, Gupta R, Spiro RH, Shah JP: Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 166: 360-365, 1993
4. Zarbo RJ, Crissman JD: The surgical pathology of head and neck cancer. Semin Oncol 15: 10-19, 1988
5. Alvi A, Johnson JT: Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head and Neck 19: 500-505, 1997
6. Vikram B: Changing patterns of failure in advanced head and neck cancer. Arch-Otolaryngol 110: 564-565, 1984
7. Hannahs KJ, Hooper JA, Sigler A: Nursing care of the head and neck cancer patient. In: Suen JY, Myers EN (eds) Cancer of the Head and Neck. Churchill Livingstone, New York, 1981 pp 839
8. Callery CD, Spiro RH, Strong EW: Changing trends in the management of squamous carcinoma of the tongue. Am J Surg 148: 449-454, 1984
9. Crile G: Excision of cancer of the head and neck - with special reference to the plan of dissection based on one hundred and thirty-two operations. J Am Med Assoc 47: 1780-1787, 1906
10. Brizel DM, Albers ME, Fisher SR, Scher RI, Richtsmeier WJ, Hars V, George SL, Huang AT, Prosnitz LR: Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck. N Engl J Med 338: 1798-1804, 1998
11. Goepfert H: Are we making any progress? Arch Otolaryngol 110: 562-563, 1984; McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck: Arch Otolaryngol Head Neck Surg 121: 278-282, 1995
12. Goepfert H: Are we making any progress? Arch Otolaryngol 110: 5622-563, 1984; McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck. Arch Otolaryngol Head Neck Surg 121: 278-282, 1995
13. Petruzzelli GJ, Benefield J, Yong S: Mechanism of lymph node metastases: current concepts. Otolaryngol Clin North Am 31: 585-599, 1998
14. Tupchong L, Scott CB, Blitzer PH, Martial VA, Lowry LD, Jacobs JR, Stetz J, Davis LW, Snow JB, Chandler RI: Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: long-term follow-up of RTOG study 73-03. Int J Rad Oncol 20: 21-28, 1991
15. Vokes EE, Weichselbaum RR, Lippman SM, Hong KW: Medical progress; head and neck cancer; N Eng J Med 328: 184-194, 1993
16. Zelefsky MJ, Raben A, Strong FW, et al.: Long term results of postoperative radiotherapy for squamous cell cancers of the head and neck (abstract 289). Proceedings of the fourth International Conference on head and neck cancer, July 1996, Toronto
17. Fisher B, Fisher ER: Barrier function of lymph node to tumor cells and crythrocytes; I Normal nodes; II Effect of X-Ray/inflammation/sensitization and tumor growth. Cancer 20: 1907-1919, 1967
18. Jones AS, Roland NJ, Field JK, Phillips DE: The level of cervical lymph node metastases: their prognostic relevance and relationship with head and neck squamous carcinoma primary, sites. Clin Otolaryngol 19: 63-69, 1994
19. Snow GB, Annyas AA, van Slooten EA, Bartelink H, Hart AAM: Prognostic factors of neck node metastasis. Clin Otolaryngol 7: 185-192, 1982
20. Leemans CR, Tiwari R, Nauta JJ, Van der Waal I, Snow GB: Regional lymph nude involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer 71: 452-456, 1993
21. Violaris NS, O'Neil D, Helliwell TR, Caslin AW, Roland NJ, Jones AS: Soft tissue cervical metastases of squamous carcinoma of the head and neck. Clin Otolaryngol 19: 394-399, 1993
22. Mendelson BC, Woods JE, Beahrs OH: Neck dissection in the treatment of carcinoma of the anterior two-thirds of the tongue. Surg Gynal Obstet 143: 75-80, 1976
23. Krause CJ, Lee JG, McCabe BF: Carcinoma of the oral cavity. Arch Otolaryngol 97: 354-358, 1973
24. Lindberg R: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446-1449, 1972
25. Shah JP, Candela FC, Poddar AK: The patterns of cervical lymph node metastases from squamous carcinoma of the oral cavity. Cancer 66: 109-113, 1990
26. Shah JP: Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 160: 405-409, 1990
27. Candela FC, Kothari K, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head & Neck 12: 197-203, 1990
28. Candela FC, Shah J, Jaqucs DP, Shah JP: Patterns of cervical node metastases from squamous carcinoma of the larynx. Arch Otolaryngol Head Neck Surg 4: 432-435, 1990
29. Bataini JP, Bernier J, Brugere J, Jaulerry Ch, Picco Ch, Brunin F: Natural history of neck disease in patients with squamous cell carcinoma of oropharynx and pharyngolarynx. Radiother Oncol 3: 245-255, 1985
30. Lindberg RD: Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 29: 1446-1449, 1972
31. Kinsey DL, James AG, Bonta JA: A study of metastatic carcinoma of the neck. Ann Surg 147: 366-374, 1958
32. Byers RM, Wolf PF, Ballantyne AJ: Rationale for elective modified neck dissection. Head Neck Surg 3: 160-167, 1988
33. Byers RM, Weber RS, Andrews T, McGill D, Kate R, Wolf P: Frequency and therapeutic implications of 'skip metastases' in the neck from squamous carcinoma of the oral tongue. Head & Neck 19: 14-19, 1997
34. Dennington ML, Carter DR, Meijers AD: Distant metastases in head and neck carcinoma. Laryngoscope 90: 196-201, 1980
35. Nishijima W, Takooda S, Tokita N, Takayama S, Sakura M: Analyses of distant metastases in squamous cell carcinoma of the head and neck and lesions above the clavicle at autopsy. Arch Otolaryngol Head Neck Surg 119: 65-68, 1993
36. Zbären P, Lehmann W: Frequency and sites of distant metastases in head and neck squamous cell carcinoma. An analysis of 101 cases at autopsy. Arch Otolaryngol Head Neck Surg 113: 762-764, 1987
37. Spiro RH: The management of neck nodes in head and neck cancer: a surgeon's view. Bull NY Acad Med 61: 629-637, 1985
38. Vernham GA, Crowther JA: Head and neck carcinoma - stage at presentation. Clin Otolaryngol 19: 120-124, 1994
39. McGuirt WF, Johnson JT, Myers EN, Rothfield R, Wagner R: Floor of mouth carcinoma. The management of the clinically negative neck. Arch Otolaryngol Head Neck Surg 121: 278-282, 1995
40. Yuen AP, Wie WI, Wong YM, Tang KC: Elective neck dissection versus observation in the treatment of early oral tongue carcinoma. Head Neck 19: 583-588, 1997
41. Van den Brekel MWM, Castelijns JA, Snow GB: Detection of lymph node metastases in the neck: radiologic criteria. Radiology 192: 617-618, 1994
42. Som PM: Detection of metastasis in cervical lymph nodes: CT and MRD criteria and differential diagnosis. Am J Rad 158: 961-969, 1992
43. Don DM, Anzai Y, Lufkin RB, Fu Y, Calcaterra TC: Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105: 669-674, 1995
44. Van den Brekel MWM, Castelijns JA, Snow GB: The size of lymph nodes in the neck on sonograms as a radiologic criterion for metastasis: How reliable is it. Am J Neuroradiol 19: 2191-2197, 1998
45. Bier J: Radical neck dissection versus conservative neck dissection for squamous cell carcinoma of the oral cavity. Rec Res Cancer Res 134: 57-62, 1994
46. Van den Brekel MWM, Castelijns JA, Stel HV, Luth WJ, Valk J, van der Waal I, Snow GB: Occult metastatic neck disease: detection with US and US-guided fine-needle aspiration cytology. Radiology 180: 457-461, 1991
47. McIvor NP, Freeman JL, Salem S, Elden L, Noyek AM, Bedard YC: Ultrasonography and ultrasound-guided fine-needle aspiration biopsy of head and neck lesions: a surgical perspective. Laryngoscope 104: 669-674, 1994
48. Van den Brekel MWM, Castelijns JA, Stel HV, Golding RP, Meyer CJ, Snow GB: Modern imaging techniques and ultrasound-guided aspiration cytology for the assessment of neck node metastases: a prospective comparative study. Eur Arch Otorhinolaryngol 250: 11-17, 1993
49. 0 neck? Proceedings of the Fourth International Conference on Head and Neck Cancer Vol IV: 548-556, 1996
50. Loree TR, Strong EW: Significance of positive margins in oral cavity squamous carcinoma. Am J Surg 160: 410-414, 1990
51. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, Goodman SN, Sidransky D: Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 332: 429-435, 1995
52. Davidson TM, Nahum AM, Astariga RW: Microscopic controlled excisions for epidermoid carcinoma et-the head and neck. Otolaryngol, Head Neck Surg 89: 244-251, 1981
53. Davidson TM, Haghighi P, Baird S, Astarita RW, Seagren S: MOHS for head and neck mucosal cancer: report on 111 patients. Laryngoscope 98: 1078-1083, 1988
54. Davidson TM, Nahum AM, Haghighi P, Astarita RW, Saltzstein SL, Seagren S: The biology of head and neck cancer: detection and control by parallel histologic sections. Arch Otolaryngol 110: 193-196, 84
55. Rouviere H: Anantomy of the Human lymphatic System. Ann Arbor: Edwards Brothers, 1938
56. Fisch UP, Sigel ME: Cervical lymphatic system as visualized by lymphography. Ann Otol 73: 869-883, 1964
57. Huang XZ, Wu JF, Spong S, Sheppard D: The integrin alpha-v-beta-6 is critical for keratinocyte migration on both its known ligand, fibronectin, and on vitronectin. J Cell Sci 111: 2189-2195, 1998
58. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a type I collagen matrix. J Cell Biol 137: 1445-1457, 1997
59. van den Brekel MWM, Stel HV, Valk P, van der Waal I, Meyer CJLM, Snow GB: Micrometastases from squamous cell carcinoma in neck dissection specimens. Eur Arch Otorhinolaryngol 249: 349-353, 1992
60. Voit C, Schoengen A, Peter RU: Increased sensitivity in early detection of submicroscopic lymph node metastases in melanoma patients. Brit J Cancer 77 Suppl 1: 29, 1998
61. Pantel K: Detection of minimal disease in patients with solid tumors. J Hematother 5: 359-367, 1996
62. Pantel K, Braun S, Passlick B, Schlimok G: minimal residual epithelial cancer: diagnostic approaches and prognostic relevance. Progr. Histochem. Cytochem 30: 1-61, 1996
63. Schlimok G, Funke I, Holzmann B, Gottlinger G, Schmidt G, Hauser H, Swierkot S, Warnecke HH, Schneider B, Koprowski H, Riethmüller G: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci 84: 8672-8676, 1987
64. Pantel K, Izbicki J, Passlick B, Angstwurm M, Häussinger K, Thetter O, Riethmüller G: Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347: 649-653, 1996
65. Lindemann F, Schlimok G, Dirschedl P, Witte J, Rielthmüller, G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer. Lancet 340: 685-689, 1992
66. Gath HJ, Heissler E, Hell B, Bier J, Riethmuller G, Pantel K: Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg 24: 351-355, 1995
67. Wollenberg B, Ollesch A, Maag K, Funke I, Wilmes E: Mikromettasen im knockenmark von patienten mil karzi-nomen des kopf-hals-bereiches. Laryngo Rhino Otol 73: 88-93, 1994
68. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, Riethmuller G, Pantel K: Limitations of reverse-transcriptase polymerase chain reliction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 15: 2701-2708, 1997
69. Dingemans A-MC, Brakenhoff RH, Postmus PE, Giaccone G. Detection of cytokeratin 19 transcripts by reverse transcriptase polymerase chain reaction in lung cancer cell lines and blood of lung cancer patients. Lab Invest 77: 213-220, 1997
70. Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56: 2488-2492, 1996
71. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marschall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252: 706-709, 1991
72. Mao L, Lee DJ, Tockman MS, Erozan YS, Askin F, Sidransky D: Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA 91: 9871-9875, 1994
73. Sidransky D: Nucleic acid-based methods for the detection of cancer. Science 278: 1054-1059, 1997
74. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D: Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Med 3: 621-624, 1997
75. Traweek ST, Liu J, Battifora H: Keratin gene expression in non-epithelial tissues: detection with polymerase chain reaction. Am J Pathol 142: 1111-1118, 1993
76. Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, Passlick B, Broelsch CE, Pantel K: Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Eng J Med 337: 1188-1194, 1997
77. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, Tollenaar RA: Micrometastases and survival in stage II colorectal cancer. N Eng J Med 339: 223-228, 1998
78. Hynes RO: Integrins: versality, modulation, and signalling in cell adhesion. Cell 69: 11-25, 1992
79. Jones PH, Harper S, Watt FM: Stem cell patterning and rate in human epidermis. Cell 80: 83-93, 1995
80. Watt FM, Jones PH: Expression and function of the keratinocyte integrins. Development Suppl: 185-192, 1993
81. Jones PH, Watt FM: Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. Cell 73: 713-724, 1993
82. Wolf GT, Carey TE, Schmaltz SP, McClatchey KD, Poore J, Glaser L, Hayashida DJ, Hsu S: Altered antigen expression predicts outcome in squamous cell carcinoma of the head and neck. J Nat Cancer Inst 82: 1566-1572, 1990
83. Jones J, Watt FM, Speight PM: Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26: 63-68, 1997
84. Thomas GJ, Jones J, Speight PM: Integrins and oral cancer. Oral Oncol 33: 381-388, 1997
85. Zhang K, Kim,JP, Woodley DT, Waleh NS, Chen YQ, Kramer RH: Restricted expression and function of laminin I-binding integrins in normal and malignant oral mucosal keratinocytes. Cell-Adhes-Commun 4: 159-174, 1996
86. Cortesina G, Bussi M, Carlevato MT, Ferro S, Panizzut B, Cavalot AL, Gervasio CF, Marchisio PC: Significance of adhesion molecules as biological prognostic factor in locally advanced laryngeal squamous cell carcinomas. Acta Otolaryngol Stockh 116: 350-352, 1996
87. Vassalli JD, Saurat JH: Cuts and scrapes? Plasmin heals. Nature Med 2: 284-285, 1996
88. Reinartz J, Schaefer B, Bechtel MJ, Kramer MD: Plasminogen activator inhibitor type-2 (PAI-2) in human keratinocytes regulates pericellular urokinase-type plasminogen activator. Exp Cell Res 223: 91-101, 1996
89. Kramer MD, Schaefer B, Reinartz J: Plasminogen activation by human keratinocytes: molecular pathways and cell-biological consequences. Biol Chem Hoppe-Seyler 376: 131-141, 1995
90. Boyd D: Invasion and metastasis, Cancer Metas Rev 15: 77-89, 1996
91. Schmitt M, Janicke F, Graeff H: Tumor-associated proteases. Fibrinolysis 4 Suppl: 3-26, 1992
92. Parolini S, Flagiello D, Cinquetti A, Gozzi R, Cristini S, Cappiello J, Nicolai P, Rusnati M, Presta M, Tosatti MM: Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 74: 1168-1174, 1996
93. Kook YH, Adamski J, Zelent A, Ossowski L: The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991, 1994
94. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM, Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 67: 333-338, 1996
95. Uhr JW, Scheuermann RH, Street NE, Vitetta ES: Cancer dormancy: opportunities for new therapeutic approaches. Nature Med 3: 505-509, 1997
96. Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 8: 838-847, 1990
97. Schuller DE, Metch B, Mattox D, McCracken JD: Prospective chemotherapy in advanced head and neck cancer: Final report of the Southwest Ontology Group. Laryngoscope 98: 1205-1211, 1988
98. Laramore GE, Scott CB, al, Sarraf M, Haselow RE, Ervin TJ, Wheeler R, Jacobs JR, Schuller DE, Gahbauer RA, Schwade JG: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol 23: 705-713, 1992
99. Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radial Oncol 19: 1347-1350, 1990
100. Browman GP, Cripps C, Hodson DI, Eapen L, Sathya J, Levine MN: Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncol 12: 2648-2653, 1994
101. Merlano M, Corvo R, Margarino M, Benasso M, Rosso R, Sertoti MR, Cavallari M, Scala M, Guenzi M, Siragusa A: Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial. Cancer 67: 915-921, 1991
102. Stupp R, Vokes E: Chemotherapy of head and neck tumors. In: Thawley SE, Panje WR, Batsakis JG, Lindberg RD (eds) Comprehensive Management of Head and Neck Tumors. W.B. Saunders Company, Philadelphia. 1999. Vol 1. pp 141-156
103. Rentschler RE, Wilbur DW, Petti GH, Chonkich GD, Hilliard DA, Camacho ES, Thorpe RB: Adjuvant methotrexate escalated to toxicity for resectable slage III and IV squamous head and neck carcinomas - a prospective, randomized study. J Clin Oncol 5: 278-285, 1987
104. Johnson JT, Myers EN, Schramm VL, Mayernik DG, Nolan TA, Sigler BA, Wagner RL: Adjuvant chemotherapy for high-risk squamous-cell carcinoma of the head and neck. J Clin Oncol 5: 456-458, 1987
105. Whiteside TL, Rabinowich H: The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46: 175-184, 1998
106. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295-306, 1998
107. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Clinical screening of monoclonal antibodies 323/A3, cSF-25, and K928 for suitability of targeting tumors in the upper-aerodigestive and respiratory tract. Nucl Med Commun 15: 613-627, 1994
108. 2. J Nucl Med 35: 775-783, 1994
109. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GAMS: Radioimmunoscintigraphy with 99m-Tc-labeled monoclonal antibody U36 and its biodistribution in patients with head and neck cancer. Clin Cancer Res I, 591-598, 1995
110. 2 in patients with head and neck cancer. Clin Cancer Res 1: 277-286, 1995
111. Van Gog FB, Visser GW, Stroomer JW, Roos JC, Snow GB, van Dongen GA: High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions. Cancer 80 Suppl: 2360-2370, 1997
112. Van Dongen GAMS, Brakenhoff RH, De Bree R, Gerretsen M, Quak JJ, Snow GH: Progress in radioimmunotherapy of head and neck cancer. Oncology Rep 1: 259-264, 1994
113. 186Re-labeled MAb E48 IgG. Cell Bioph 24: 135-142, 1994
114. 186Re-labeled monoclonal antibody E48 IgG mediated therapy of human head and neck squamous cell carcinoma xenografts. Cancer Res 53: 3524-3229, 1995
115. Van Gog FB, Brakenhoff RH, Stigter-van Walsum M, Snow GB, van Dongen GA: Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy of the treatment of residual head and neck cancer. Int J Cancer 77: 13-18, 1998
116. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55: 1-6, 1995
117. Clayman GL, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16: 2221-2232, 1998
118. Breau RL, Clayman GL: Gene therapy for head and neck cancer. Curr Opin Oncol 8: 227-231, 1996
119. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996
120. Heise C, Sampson-Johannes A, Williams A, McCormick F, Vonhoff DD, Kirn DH: Onyx-015, an Elb gentattenuated adenovirus, causes tumor-specitic cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 3: 639-645, 1997
121. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW: p53-dependent cell death/apoptosis is required for a productive adenovirus, infection. Nature Med 4: 1068-1072, 1998
122. Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, Zurhausen H: Replication of onyx-015, a potential anti-cancer adenovirus, is independent of p53 status in tumor cells. J Virol 72: 9470-9478, 1998
123. Rocco JW, Li D, Liggett WH Jr, Duan L, Sounders JK Jr, Sidransky D, O'Malley BW Jr: p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 4: 1697-1704, 1998
124. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech 14: 1574-1578, 1996
125. Dmitriev I, Krasnykh V, Miller CR, Wang MH, Kashentseva E, Mikbecva G, Belousova N, Curiel DT: An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 72: 9706-9713, 1998
126. Cooper JS, Pajak TF, Rubin P, Tupchong L, Brady LW, Leibel SA, Laramore GE, Marcial VA, Davis LW, Cox JD: Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol 17: 449-456, 1989
127. Licciardello JT, Spitz MR, Hong WK: Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radial Oncol 17: 467-476, 1989
128. Schaart LH, Ozsahin M, Zhang GN, Touboul E, De-Vataire F, Andolenko P, Lacau-Saint-Guily J, Laugier A, Schlicnger M: Synchronous and metachronous head and neck carcinomas. Cancer 74: 33-38, 1994
129. Slaughter DP, Southwick HW, Smejkal W: 'Field cancerisation' in oral stratified squamous epithelium: Clinical implication of multicentric orgin. Cancer 6: 963-968, 1953
130. Warren S, Gates O: Multiple primary malignant tumors: a survey of the literature and a slatistical study. Am J Cancer 16: 1358-1414, 1932
131. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323: 795-801, 1990
132. Bedi GC, Westra WH, Gabrielson E, Koch W, Sidransky D: Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res 56: 2484-2487, 1996
133. Leong PP, Rezai B, Koch WM, Reed A, Eisele D, Lee DJ, Sidransky D, Jen J, Westra WH: Distinguishing second primary tumors from lung metastases in patients with head and neck squarmous cell carcinoma. J Nat Cancer Inst 90: 972-977, 1998
134. Cloos J, Braakhuis BJM, Steen I, Copper MP, de Vries N, Naula JJP, Snow GB: Increased mutagen sensitivity in head-and-neck squamous-cell carcinoma patients, particularly those with multiple primary tumors. Int J Cancer 56: 816-819, 1994
135. Cloos J, Spitz MR, Schantz SP, Hsu TC, Zhang Z, Tobi H, Braakhuis BJM, Snow GB: Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 530-535, 1996.
136. De Vries N, Van Zandwijk N, Pastorino U: Chemoprevention of second primary tumours in head and neck cancer in Europe: Euroscan. Eur J Cancer 30B: 367-368, 1994